Trials / Completed
CompletedNCT04871776
Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 3,671 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upcoming primary care clinic visit, will be randomized to one of three messaging arms: 1) "why" messaging, 2) "how" messaging, or 3) standard of care ("usual care"). Messages will be sent via the electronic patient portal a few days in advance of their office visit. The primary outcome will be the rate of booster vaccination at the targeted visit. The secondary outcome will be the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit. Subgroup analyses to assess for any association of patient characteristics with intervention responsiveness will be exploratory.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Messaging informed by construal level theory | Messages are informed by construal level theory, which suggests that emphasizing "why" elicits more abstract thinking, or high-level construals, and can induce an emotional mindset, which could challenge an individual's sense of identity, autonomy, or political preferences. Conversely, emphasizing "how" is more cognitive and evokes concrete thinking, or low-level construals, and encourages a planning or implementation mindset, which may be better for encouraging vaccine uptake. |
| BEHAVIORAL | Usual Care | Usual messaging sent by Mass General Brigham |
Timeline
- Start date
- 2022-02-18
- Primary completion
- 2022-05-27
- Completion
- 2022-08-17
- First posted
- 2021-05-04
- Last updated
- 2024-01-16
- Results posted
- 2024-01-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04871776. Inclusion in this directory is not an endorsement.